logo
Share SHARE
FONT-SIZE Plus   Neg

EveryWare Global, ROI Acquisition Complete Business Combination

EveryWare Global, Inc. and ROI Acquisition Corp. (ROIQ: Quote) said Tuesday that they have completed their business combination deal.

This follows the receipt of stockholder approval at ROI's Special Meeting in lieu of the 2013 Annual Meeting of Stockholders and receipt of public warrantholder approval at ROI's Special Meeting of Public Warrantholders held today.

As a result of the completion of the deal, EveryWare becomes a public company.

EveryWare has applied to continue to list its shares of common stock on The Nasdaq Stock Market under the symbol "EVRY". EveryWare believes that it will be able to satisfy the round lot holder requirement promptly following the closing so as to complete its application for continued listing.

Effective May 22, the ticker symbol for ROI's common stock on Nasdaq will be changed from "ROIQ" to "EVRY" and the combined company will notify Nasdaq that it plans to voluntarily delist its outstanding warrants, which currently trade on Nasdaq under the symbol "ROIQW," because it plans to have the warrants quoted on the OTC market. The combined company expects that quotation of the warrants on the OTC market will commence on or about June 3 under the symbol "EVRYW".

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Chipotle Mexican Grill Inc. (CMG) on Monday reported a surge in profit for the first quarter, as revenues climbed 20 percent on new restaurant openings and strong same-restaurant sales. Earnings for the quarter trounced Wall Street expectations, but revenues fell short of estimates, hurt largely... Yahoo reported a plunge in profit, hurt by lower prices for display ads as well as one-time charges. Its results fell short of Street estimates, denoting the challenges CEO Marissa Mayer faces in implementing her turnaround plans at the Internet company. Amgen Inc. (AMGN) on Tuesday reported a surge in profit for the first quarter, as revenues grew 11 percent on better pricing and strong demand with research costs falling. Both earnings and revenues for the quarter trumped analysts' estimates. Moving ahead, the drug maker raised its outlook for the full...
comments powered by Disqus
Follow RTT